Tuesday, July 17, 2018
 
 
Company News: Page (1) of 1 - 07/11/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
OrigiMed Collaborates with Illumina to Further Develop and Promote its Advanced Clinical Molecular Tumor Applications
 
(July 11, 2018)

SHANGHAI, July 11, 2018 /PRNewswire/ -- OrigiMed announces an agreement with Illumina in Shanghai, China. It will develop and promote its advanced molecular clinical tumor applications to the public based on the Next Generation Sequencing (NGS) technology of Illumina. This marks further cooperation between Illumina and Chinese enterprises. It also signals that genomics technology will play an increasingly important future role in the fast-developing market of precise diagnosis of cancer.

Signing Ceremony

Recently, NGS has emerged as the key technology in precision medicine. The Chinese market has huge potential to apply NGS technology because of its large cancer patient population - more than 4 million new cancer patients identified in China each year. The cooperation between OrigiMed and Illumina means that the world's leading NGS technology will cover more widely the Chinese market. As an important part of the cooperation, Illumina will provide NGS instruments and related reagents, and OrigiMed will focus on the clinical applications in tumor molecular diagnosis and provide self-developed and a patterned bioinformatics solution to the medical institutions. In the future, OrigiMed plans to develop a total sequencing solution for clinical applications.



About OrigiMed

OrigiMed is a medical science and technology transforming company which focuses on developing new technologies and clinical applications for all types of cancer patients. By carrying out more comprehensive and high-throughput methods, leveraging wholesome bioinformatics analysis and clinical annotation, we identify cancer specific molecular markers and genomic features to guide targeted or immuno-therapy, ultimately aim to fortify the evolution of cancer precision medicine in China.

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/origimed-collaborates-with-illumina-to-further-develop-and-promote-its-advanced-clinical-molecular-tumor-applications-300679895.html

SOURCE OrigiMed

Copyright 2014 PR Newswire. All Rights Reserved


Page: 1


Related Keywords:Science,Medical,Agricultural Science,Biology,Genetics,Cancer,Science,
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Personal Care Home Consultant Lynn Marting Helps Families Find the Right Facility for Aging Loved Ones
  • Global Cosmetic Chemicals Industry
  • HMP's 8th Annual Amputation Prevention Symposium Expected to Draw 800 Clinicians to Chicago to Join the CLI Revolution
  • Progressive Care Inc. Announces Month-End Sales Figures Showing Increase in Year-Over-Year Prescriptions Filled in June 2018
  • Mount Sinai Health System and Arena Address AI-Driven Hiring for Healthcare at Leading Industry Conference

    Cancer
  • Camurus Announces PDUFA Date for CAM2038 for the Treatment of Opioid use Disorder
  • Presage Biosciences Closes Series D Financing with Takeda and Celgene, and Announces Appointment of Richard Klinghoffer, PhD as Chief Executive Officer
  • Presage Biosciences Closes Series D Financing with Takeda and Celgene, and Announces Appointment of Richard Klinghoffer, PhD as Chief Executive Officer
  • Corporate Whistleblower Center Now Targets Hospice Providers Ripping Off Medicare And Urges Their Employees with Proof a of Wrongdoing to Call About Rewards -- Don't Get Mad, Get Even
  • Corporate Whistleblower Center Now Targets Hospice Providers Ripping Off Medicare And Urges Their Employees with Proof a of Wrongdoing to Call About Rewards -- Don't Get Mad, Get Even
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines